Lu K, Yin M B, McGuire J J, Bonmassar E, Rustum Y M
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Italy.
Biochem Pharmacol. 1995 Jul 31;50(3):391-8. doi: 10.1016/0006-2952(95)00135-m.
N-[5-[N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2-thenoyl]-L-glutamic acid (ZD1694) is a folate-based thymidylate synthase (TS; EC 2.1.1.45) inhibitor. Metabolism to higher chain length polyglutamates is essential for its optimal cytotoxic effect. A ZD1694-resistant (300-fold) human ileocecal carcinoma cell line (HCT-8/DW2) was developed, and its mechanism of resistance was evaluated. TS activities in situ and TS protein levels in the HCT-8 parental line and HCT-8/DW2 were similar (168 +/- 47 vs 137 +/- 25 pmol/hr/10(6) cells and 2.05 +/- 0.28 vs 2.07 +/- 0.19 pmol/mg protein, respectively). The IC50 values of ZD1694 for TS inhibition in cell-free extracts were similar in both lines, but the IC50 of ZD1694 for TS inhibition in situ in HCT-8/DW2 cells was 27- and 268-fold higher than that in HCT-8 cells at 0 and 24 hr, respectively, after a 2-hr drug exposure. Folylpolyglutamate synthetase (FPGS; EC6.3.2.17) activity was significantly lower in resistant HCT-8/DW2 cells as compared with parental HCT-8 cells (88 +/- 40 vs 1065 +/- 438 pmol/hr/mg protein when ZD1694 was used as substrate). The combined endogenous pool of methylenetetrahydrofolate and tetrahydrofolate in HCT-8/DW2 cells was also decreased. In addition, HCT-8/DW2 cells accumulated lower levels of methotrexate (MTX) in a 2-hr period, although the initial velocity of MTX transport was similar to that in parental HCT-8 cells. The lower level of FPGS activity and the lower level of (anti)folate accumulation in HCT-8/DW2 correlated with drug resistance and with the higher IC50 of ZD1694 for in situ TS inhibition. In addition, drug resistance was also correlated with the rapid recovery of in situ TS activity after drug treatment. In brief, in this highly ZD1694-resistant HCT-8 cell line, resistance is associated with decreased FPGS activity, which, in turn, affects the metabolism of ZD1694 and consequently the extent and duration of in situ TS inhibition by the drug.
N-[5-[N-(3,4-二氢-2-甲基-4-氧代喹唑啉-6-基甲基)-N-甲基氨基]-2-噻吩甲酰基]-L-谷氨酸(ZD1694)是一种基于叶酸的胸苷酸合成酶(TS;EC 2.1.1.45)抑制剂。代谢生成更高链长的多聚谷氨酸对于其最佳细胞毒性作用至关重要。构建了一株对ZD1694耐药(300倍)的人回盲部癌细胞系(HCT-8/DW2),并对其耐药机制进行了评估。HCT-8亲代细胞系和HCT-8/DW2中的TS原位活性和TS蛋白水平相似(分别为168±47 vs 137±25 pmol/小时/10⁶个细胞以及2.05±0.28 vs 2.07±0.19 pmol/毫克蛋白)。在无细胞提取物中,ZD1694对TS抑制的IC50值在两株细胞系中相似,但在2小时药物暴露后,0小时和24小时时,HCT-8/DW2细胞中ZD1694对TS原位抑制的IC50分别比HCT-8细胞高27倍和268倍。与亲代HCT-8细胞相比,耐药的HCT-8/DW2细胞中的叶酰聚谷氨酸合成酶(FPGS;EC6.3.2.17)活性显著降低(以ZD1694为底物时,分别为88±40 vs 1065±438 pmol/小时/毫克蛋白)。HCT-8/DW2细胞中亚甲基四氢叶酸和四氢叶酸的内源性总和也有所降低。此外,尽管甲氨蝶呤(MTX)的初始转运速度与亲代HCT-8细胞相似,但HCT-8/DW2细胞在2小时内积累的MTX水平较低。HCT-8/DW2中较低的FPGS活性水平和较低的(抗)叶酸积累水平与耐药性以及ZD1694对原位TS抑制的较高IC50相关。此外,耐药性还与药物处理后原位TS活性的快速恢复相关。简而言之,在这种对ZD1694高度耐药的HCT-8细胞系中,耐药性与FPGS活性降低有关,这反过来又影响ZD1694的代谢,从而影响药物对原位TS抑制的程度和持续时间。